Aerosol fluoroquinolone formulations for improved pharmacokinetics
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/397
A61K-031/535
A61P-011/06
A61K-031/5383
A61K-009/00
A61K-031/4375
A61K-031/47
A61K-031/538
A61K-047/02
A61K-031/536
출원번호
US-0132122
(2016-04-18)
등록번호
US-9717738
(2017-08-01)
발명자
/ 주소
Griffith, David C.
Dudley, Michael N.
Surber, Mark W.
Bostian, Keith A.
Rodny, Olga
출원인 / 주소
Horizon Orphan LLC
대리인 / 주소
Mintz Levin Cohn Ferris Glovsky and Popeo, P.C.
인용정보
피인용 횟수 :
2인용 특허 :
159
초록▼
The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infection
The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.
대표청구항▼
1. A method of treating a chronic pulmonary infection due to Pseudomonas aeruginosa in a subject with cystic fibrosis in need thereof, the method comprising administering to the lungs of the subject with cystic fibrosis an aerosol of a solution comprising about 100 mg/ml of levofloxacin and about 20
1. A method of treating a chronic pulmonary infection due to Pseudomonas aeruginosa in a subject with cystic fibrosis in need thereof, the method comprising administering to the lungs of the subject with cystic fibrosis an aerosol of a solution comprising about 100 mg/ml of levofloxacin and about 200 mM of magnesium chloride; wherein the solution has a pH from about 5 to about 7 and an osmolality from about 350 mOsmol/kg to about 400 mOsmol/kg, to treat the chronic pulmonary infection due to Pseudomonas aeruginosa. 2. The method of claim 1, wherein about 240 mg of levofloxacin is administered to the subject. 3. A method of treating a Pseudomonas pulmonary infection in a subject in need thereof, the method comprising administering to the lungs of the subject an aerosol of a solution comprising from about 90 mg/ml to about 110 mg/ml of levofloxacin and from about 190 mM to about 210 mM of a magnesium cation to treat the Pseudomonas pulmonary infection. 4. The method of claim 3, wherein the Pseudomonas is Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, or a combination of two or more thereof. 5. The method of claim 3, wherein the subject has cystic fibrosis. 6. The method of claim 3, wherein the solution comprises about 100 mg/ml of levofloxacin and about 200 mM of the magnesium cation; wherein the solution has a pH from about 5 to about 7 and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg; and wherein from about 200 mg to about 280 mg of levofloxacin is administered to the subject. 7. The method of claim 3, wherein from about 230 mg to about 250 mg of levofloxacin is administered to the subject. 8. The method of claim 4, wherein the Pseudomonas is Pseudomonas aeruginosa. 9. The method of claim 6, wherein the solution has a pH from about 6.0 to about 6.5 and an osmolality from about 350 mOsmol/kg to about 400 mOsmol/kg. 10. The method of claim 3, wherein the magnesium cation is in the form of magnesium chloride. 11. A method of treating a Mycobacterium pulmonary infection in a subject in need thereof, the method comprising administering to the lungs of the subject an aerosol of a solution comprising from about 90 mg/ml to about 110 mg/ml of levofloxacin and from about 190 mM to about 210 mM of a magnesium cation to treat the Mycobacterium pulmonary infection. 12. The method of claim 11, wherein the Mycobacterium is Mycobacterium avium, Mycobacterium intracellulare, or a combination thereof. 13. The method of claim 11, wherein the solution comprises about 100 mg/ml of levofloxacin and about 200 mM of the magnesium cation; wherein the solution has a pH from about 5 to about 7 and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg; and wherein from about 200 mg to about 280 mg of levofloxacin is administered to the subject. 14. The method of claim 13, wherein from about 230 mg to about 250 mg of levofloxacin is administered to the subject. 15. The method of claim 13, wherein about 240 mg of levofloxacin is administered to the subject. 16. The method of claim 13, wherein the solution has a pH from about 6.0 to about 6.5 and an osmolality from about 350 mOsmol/kg to about 400 mOsmol/kg. 17. The method of claim 11, wherein the magnesium cation is in the form of magnesium chloride. 18. A method of treating bronchiectasis in a subject in need thereof, the method comprising administering to the lungs of the subject an aerosol of a solution comprising from about 90 mg/ml to about 110 mg/ml of levofloxacin and from about 190 mM to about 210 mM of a magnesium cation to treat the bronchiectasis. 19. The method of claim 18, wherein the solution comprises about 100 mg/ml of levofloxacin and about 200 mM of the magnesium cation; wherein the solution has a pH from about 5 to about 7 and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg; and wherein from about 200 mg to about 280 mg of levofloxacin is administered to the subject. 20. The method of claim 19, wherein from about 230 mg to about 250 mg of levofloxacin is administered to the subject. 21. The method of claim 20, wherein from about 230 mg to about 250 mg of levofloxacin is administered to the subject. 22. The method of claim 19, wherein the solution has a pH from about 6.0 to about 6.5 and an osmolality from about 350 mOsmol/kg to about 400 mOsmol/kg. 23. The method of claim 18, wherein the magnesium cation is in the form of magnesium chloride. 24. A method of treating a bacterial pulmonary infection in a subject in need thereof, the method comprising administering to the lungs of the subject an aerosol of a solution comprising from about 90 mg/ml to about 110 mg/ml of levofloxacin and from about 190 mM to about 210 mM of a magnesium cation to treat the bacterial pulmonary infection. 25. The method of claim 24, wherein the solution comprises about 100 mg/ml of levofloxacin and about 200 mM of the magnesium cation; wherein the solution has a pH from about 5 to about 7 and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg; and wherein from about 200 mg to about 280 mg of levofloxacin is administered to the subject. 26. The method of claim 24, wherein the magnesium cation is in the form of magnesium chloride. 27. The method of claim 25, wherein about 240 mg of levofloxacin is administered to the subject. 28. The method of claim 25, wherein the solution has a pH from about 6.0 to about 6.5 and an osmolality from about 350 mOsmol/kg to about 400 mOsmol/kg. 29. The method of claim 24, wherein the bacterial pulmonary infection is caused by Pseudomonas aeruginosa, Pseudomonas fluorescens, Pseudomonas acidovorans, Pseudomonas alcaligenes, Pseudomonas putida, Stenotrophomonas maltophilia, Aeromonas hydrophilia, Escherichia coli, Citrobacter freundii, Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Enterobacter cloacae, Enterobacter aerogenes, Klebsiella pneumoniae, Klebsiella oxytoca, Serratia marcescens, Morganella morganii, Proteus mirabilis, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia stuartii, Acinetobacter calcoaceticus, Acinetobacter haemolyticus, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, Yersinia intermedia, Bordetella pertussis, Bordetella parapertussis, Bordetella bronchiseptica, Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus haemolyticus, Haemophilus parahaemolyticus, Haemophilus ducreyi, Pasteurella multocida, Pasteurella haemolytica, Helicobacter pylori, Campylobacter fetus, Campylobacter jejuni, Campylobacter coli, Borrelia burgdorferi, Vibrio cholera, Vibrio parahaemolyticus, Legionella pneumophila, Listeria monocytogenes, Neisseria gonorrhoeae, Neisseria meningitidis, Burkholderia cepacia, Francisella tularensis, Kingella, Moraxella, Bacteroides fragilis, Bacteroides distasonis, Bacteroides 3452A homology group, Bacteroides vulgatus, Bacteroides ovalus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides eggerthii, Bacteroides splanchnicus, Corynebacterium diphtheriae, Corynebacterium ulcerans, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus milleri; Streptococcus (Group G); Streptococcus (Group C/F); Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, Staphylococcus intermedius, Staphylococcus hyicus subsp. hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saccharolyticus, Clostridium difficile, Clostridium perfringens, Clostridium tetini, Clostridium botulinum, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium leprae, Chlamydia pneumoniae, Mycoplasma pneumoniae, or a combination of two or more thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (159)
Sanchez Joseph P. (Canton MI) Trehan Ashok K. (Ann Arbor MI), 5-amino and 5-hydroxy-6-fluoroquinolones as antibacterial agents.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
James N. Schmidt CA; Jerry Grychowski ; Daniel K. Engelbreth CA; Robert Morton CA; Martin P. Foley CA, Aerosol medication delivery apparatus and system.
Osbakken, Robert S.; Hale, Mary Anne; Leivo, Frederick T.; Munk, James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Gordeev, Mikhail F.; Patel, Dinesh V.; Barbachyn, Michael R.; Gage, James R., Antimicrobial quinolone derivatives and use of the same to treat bacterial infections.
Gordeev, Mikhail F.; Patel, Dinesh V.; Barbachyn, Michael R.; Gage, James R., Antimicrobial quinolone derivatives and use of the same to treat bacterial infections.
Hodson Peter D. (Trowell GB3) Baum Eric A. (Loughborough GB3) Smith David K. (Loughborough GB3) Kuepper Anton (Kaarst DEX) Wilby Matthew J. (Loughborough GB3), Breath actuated inhaler having an electromechanical priming mechanism.
Newell Robert E. (Pinner GB2) Rand Paul K. (Nitchin GB2) Fitzsimmons Robert A. (Barnard Castle GB2), Devices for administering medicaments to patients.
Casper, Robert A.; Leith, Frank A.; Gardner, David L.; Snow, John M.; Lyon, Zachary W.; Farrar, David S., Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament.
Mulhauser Paul (New York NY) Karg Jeffrey (Waldwick NY) Foxen Thomas (Brooklyn NY) Brooks Christopher J. (Glen Head NY), Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same.
Domagala John M. (Canton MI) Kiely John S. (Ann Arbor MI) Schroeder Mel C. (Dexter MI), Individual stereosiomers of 7-[3-(aminoalkyl)-1-pyrrolidinyl]-quinolones and naphthyridones as antibacterial agents.
Burns James S. (Darien CT) Marshak Daniel R. (Cold Spring Harbor NY), Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means.
Ambrosio Thomas J. ; Ashley Charles R. ; Bilanin Alan J. ; Huck Charles M. ; Kaufman Andrew E. ; Kenyon David J. ; Manthena Srinivas ; Sochon Henry R. ; Wilkinson Ken ; Yang Tsong-Toh, Inhaler for powdered medications.
Hess Joseph,CHX ; Bo Hu,CHX ; Weber Raphael,CHX ; Ortega Isabel,CHX ; Barraud Cedric,CHX ; van der Schoot Bart,CHX ; de Rooij Nicolaas Frans,CHX ; de Heij Bas,CHX, Liquid droplet spray device for an inhaler suitable for respiratory therapies.
Zoltan Bart J. (Old Tappan NJ) Laube Beth L. (Baltimore MD) Adams ; III George K. (Baltimore MD) Bow Clark F. (Newton NJ) Devito Ralph J. (Stanhope NJ) Harrington Walter (Flanders NJ) Hoffman Louis S, Medication delivery system phase two.
Smith Adrian E. ; Burr John D. ; Etter Jeffery W. ; Axford George S. ; Lyons Shirley W. ; Platz Robert M., Method and apparatus for dispersion of dry powder medicaments.
Blineau Joseph (Rennes FRX) Pommier Daniel (Mordelles FRX) Thomas Claude (Chasne sur Illet FRX), Multiplex channels for continuous flow for numerical signal.
Nowacki Christopher (Arlington Heights IL) Brisson Alfred G. (Kildeer IL) Dela-Cruz Exequiel (Arlington Heights IL), Pediatric asthmatic medication inhaler.
Arnold Klaus (Ingelheim am Rhein DEX) Grass Peter (Ingelheim am Rhein DEX) Knecht Adolf (Freiburg DEX) Roos Robert (Ingelheim am Rhein DEX) Sluke Gerhard (Ingelheim am Rhein DEX) Thieme Herbet (Ingel, Powders for inhalation.
Knight Jack V. (Houston TX) Wilson ; Jr. Samuel Z. (Houston TX), Small particle aerosol generator for treatment of respiratory disease including the lungs.
Barbachyn Michael R. (Kalamazoo MI) Brickner Steven J. (Portage MI) Hutchinson Douglas K. (Kalamazoo MI), Substituted oxazine and thiazine oxazolidinone antimicrobials.
Welsh, Michael J.; Zabner, Joseph, Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections.
Griffith, David C.; Dudley, Michael N.; Surber, Mark W.; Bostian, Keith A.; Rodny, Olga, Aerosol fluoroquinolone formulations for improved pharmacokinetics.
Loutit, Jeffery S.; Morgan, Elizabeth E.; Dudley, Michael N.; Griffith, David C.; Lomovskaya, Olga, Use of aerosolized levofloxacin for treating cystic fibrosis.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.